Reconstitution of NADPH oxidase activity in human X-linked chronic granulomatous disease myeloid cells after stable gene transfer using a recombinant adeno-associated virus 2 vector

Blood Cells, Molecules, and Diseases

Volumn 24, Issue 4, 1998, Pages 522-538

  Li, Ling Lin ^a   Dinauer, Mary C ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus 2; Chronic granulomatous disease; Elongation factor 1 ; Gene therapy; Neutrophils

Indexed keywords

COMPLEMENTARY DNA; RECOMBINANT RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VIRUS VECTOR;

ARTICLE; BONE MARROW CULTURE; CONTROLLED STUDY; DNA DETERMINATION; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; ENZYME RECONSTITUTION; GENE SILENCING; GENE THERAPY; GENETIC TRANSDUCTION; GRANULOMATOSIS; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECOMBINANT GENE; RNA ANALYSIS; TREATMENT OUTCOME;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; MURINAE;

EID: 0032451162     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1998.0216     Document Type: Article

References (71)

1. 1. Curnutte J, Orkin S, Dinauer M. Genetic disorders of phagocyte function, in Stamoyannopoulos G (ed): The Molecular Basis of Blood Diseases (ed 2nd). Philadelphia, W.B. Saunders, pp 493-522, 1994.
2. 2. Dinauer M. The respiratory burst oxidase and the molecular genetics of chronic granulomatous disease. Crit Rev Clin Lab Sci 30:329-369, 1993.
3. 3. Weening R, Adriaansz L, Weemaes C, Lutter R, Roos D: Clinical differences in chronic granulomatous disease inpatients with cytochrome b-negative or cytochrome b positive neutrophils. J Pediatr 107:102-104, 1985.
4. 4. Finn A, Hadzik N, Morgan G, Strobel S, Levinsky R. Prognosis of chronic granulomatous disease. Arch Dis Child 65:942-945, 1990.
5. 5. Thrasher A, Keep N, Wientjes F, Segal A. Review: Chronic granulomatous disease. Biochim Biophys Acta 1227:1-24, 1994
6. 6. Roos D, de Boer M, Kuribayashi F, et al. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 87:1663-1681, 1996.
7. 7. Malech H, Bauer T, Hickstein D. Prospects for Gene Therapy of Neutrophil Defects. Semin Hematol 34:355-361, 1997.
8. 8. Weinberg K, Kohn D. Gene therapy for congenital immunodeficiency diseases. Immunol Allergy Clin NA 16:453-476, 1996.
9. 9. Karlsson S. Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 78:2481-2492, 1991.
10. 10. Malech H, Maples P, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 94:12133-12138, 1997.
11. 558 defective forms of chronic granulomatous disease. Blood 84:53-58, 1994.
12. phox-deficient chronic granulomatous disease. Proc Natl Acad Sci USA 90:7446-7450, 1993.
13. 13. Bjorgvinsdottir H, Ding C, Pech N, Gifford M, Li L, Dinauer M. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 89:41-48, 1997.
14. 14. Porter C, Parker M, Levinsky R, Collins M, Kinnon C. X-linked chronic granulomatous disease: Correction of NADPH oxidase defect by retrovirus-mediated expression of gp91-phox. Blood 82:2196-2202, 1993
15. 15. Kume A, Dinauer M. Retrovirus-mediated reconstitution of respiratory burst activity in X-linked chronic granulomatous disease cells. Blood 84:3311-3316, 1994.
16. phox. Blood 88:1834-1840, 1996.
17. 17. Smith A. Viral vectors in gene therapy. Annu Rev Microbiol 49:807-838, 1995.
18. 18. Kotin R. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 5:793-801, 1994.
19. 19. Srivastava A. Parovirus-based vectors for human gene therapy. Blood Cells 20:531-538, 1994.
20. 20. Hallek M, Girod A, Braun-Falco M, Wendtner C-M, Bogedain C, Horer M. Recombinant adeno-associated virus vectors. Curr Res Mol Ther In press, 1998.
21. 21. Srivastava A, Lusby E, Berns K. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol 45:555-564, 1983.
22. 22. Samulski R, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome. EMBO J 10:3941-3950, 1991.
23. 23. Kotin R, Siniscalco M, Samulski R, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87:2211-2215, 1990.
24. 24. Zhou S, Cooper S, Kang L, et al. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med 179:1867-1875, 1994.
25. 25. Walsh C, Liu J, Xiao X, Young N, Nienhuis A, Samulski R. Regulated high level expression of a human γ-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci USA 89:7257-7261, 1992.
26. 26. Einerhand M, Antoniou M, Zolotukhin S, et al. Regulated high-level human beta-globin gene expression in erythroid cells following recombinant adeno-associated virus-mediated gene transfer. Gene Ther 2:336-343, 1995
27. 27. Lubovy M, McCune S, Dong J, Prehal J, Townes T, Prehal J. Stable transduction of recombinant adeno-associated virus into hematopoietic stem cells from normal and sickle cell patients. Biol Blood Marrow Transplant 2:24-30, 1996.
28. 28. Fisher-Adams G, Wong K, Podsakoff G, Forman S, Chatterjee S. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 88:492-504, 1996.
29. 29. Malik P, McQuiston S, Yu X-J, et al. Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. J Virol 71:1776-1783, 1997.
30. 30. Ponnazhagan S, Yoder M, Srivastava A. Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo. J Virol 71:3098-3104, 1997.
31. 31. Goodman S, Xiao X, Donahue R, et al. Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood 84:1492-1500, 1994.
32. 32. Miller J, Donahue R, Sellers S, Samulski R, Young N, Nienhuis A. Recombinant adeno-associated virus (rAAV)-mediated expression of a human γ-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad USA 91:10183-10187, 1994.
33. 33. Walsh C, Nienhuis A, Samulski R, et al. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest 94:1440-1448, 1994.
34. 34. Ponnazhagan S, Mukherjee P, Wang X, et al. Adeno-Associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: Donor variation and correlation of transgene expression with cellular differentiation. J Virol 71:8262-8267, 1997.
35. 35. Thrasher A, de Alwis M, Casimir C, et al. Functional reconstitution of the NADPH-oxidase by adeno-associated virus gene transfer. Blood 86:761-765, 1995.
36. 36. Rutledge E, Russell D. Adeno-associated virus vector integration junctions. J Virol 71:8429-8436, 1997.
37. 37. Ponnazhagan S, Erikson D, Kearns W, et al. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther 8:275, 1997
38. 38. Russell D, Miller A, Alexander L. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 91:8915-8919, 1994.
39. 39. Kearns W, Afione S, Fulmer S, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther 3:748-755, 1996.
40. 40. Linden R, Winocour E, Berns K. The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci USA 93:7966-7972, 1996
41. 41. Giraud C, Winocour E, Berns K. Recombinant junctions formed by site-specific integration of adeno-associated virus into an episome. J Virol 69:6917-6924, 1995
42. 42. Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucl Acids Res 18:5322, 1990.
43. 43. Wakabayashi-Ito N, Nagata S. Characterization of the regulatory elements in the promoter of the human elongation factor-1αa gene. J Biol Chem 47:29831-29837, 1994.
44. phox. Proc Natl Acad Sci USA 90:9832-9836, 1993
45. 45. Wang X, Yoder M, Zhou S, Srivastava A. Parovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cells. Proc Natl Acad Sci USA 92: 12416, 1995
46. phox cDNA and functional expression in a human X-linked chronic granulomatous disease cell line. Blood 87:2005-2010, 1996.
47. 47. Tucker K, Lilly M, Heck L, Rado T. Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. Blood 70:372-378, 1987.
48. 48. Wang X-S, Qing K, Ponnazhagan S, Srivastava A. Adeno-associated virus type 2 DNA replication in vivo: Mutation analyses of the D sequence in viral inverted terminal repeats. J Virol 71:3077-3082, 1997.
49. 49. Sambrook J, Fritsch E, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989.
50. 50. Wang X-S, Selvarangan P, Srivastava A. Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J Virol 70:1668-1677, 1996.
51. 51. Dinauer M, Parkos C, Jesaitis A, Orkin S. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature 327:717-720, 1987.
52. 52. Pollock J, Williams D, Gifford M, et al. Mouse Model of X-linked chronic granulomatous disease, an inherited defect in phagocytes superoxide production. Nat Genet 9:202-209, 1995
53. 53. Kim D, Uetsuki T, Kaziro Y, Yamaguchi N, Sugano S. Use of the human elongation factor 1α promoter as a versatile and efficient expression system. Gene 91:217-223, 1990.
54. 54. Kim D, Harada T, Saito I, Miyamura T. An efficient expression vector for stable expression in human liver cells. Gene 134:307-308, 1993.
55. 55. Brenner M: Gene transfer to hematopoietic cells. N Engl J Med 335:337-339, 1996.
56. 56. Verma I, Somia N. Gene therapy promises, problems, and prospects. Nature 389:239-242, 1997.
57. 57. Miller A. Human Gene Therapy Comes Of Age. Nature 357:455-460, 1992.
58. 58. Cornetta K, Fan Y. Retroviral Gene Therapy in Hematopoietic Diseases. J Clin Apheresis 12:187-193, 1997.
59. 558 using site-directed mutagenesis. J Biol Chem 273:6575-6581, 1998.
60. + cells. Hum Gene Ther 9:1561-1570, 1998.
61. 61. Thrasher A, de Alwis M, Casimir C, et al. Generation of recombinant adeno-associated virus (rAAV) from an adenoviral vector and functional reconstitution of the NADPH-oxidase. Gene Ther 2:481-485, 1995.
62. 62. Maly F, Cross A, Jones O, et al. The superoxide generating system of B cell lines: Structural homology with the phagocytic oxidase and triggering via surface Ig. J Immunol 140:2334-2339, 1988.
63. 63. Volkman DJ, Buescher E, Gallin JI, Fauci AS. B cell lines as models for inherited phagocytic diseases: abnormal superoxide generation in chronic granulomatous disease and giant granules in Chediak-Higashi syndrome. J Immunol 133:3006-3009, 1984.
64. 64. Chetty M, Thrasher A, Abo A, Casimir C. Low NADPH oxidase activity in Epstein-Barr-virus-immortalized B-lymphocytes is due to a post-transcriptional block in expression of cytochrome b558. Biochem J 306:141-145, 1995.
65. 65. Chen W, Bailey E, McCune S, Dong J-Y, Townes T. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 94:5798-5803, 1997.
66. 66. Xiao X, Li J, Samulski R. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70:8098-8108, 1996
67. 67. Fisher K, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 3:306-312, 1997.
68. 68. Herzog R, Hagstrom J, Kung S-H, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94:5804-5809, 1997.
69. 69. Koeberl D, Alexander I, Halbert C, Russell D, Miller A. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 94:1426-1431, 1997.
70. 70. Itou T, Miyamura K, Iijima N, Emi N, Tanimoto M, Salto H. Recombinant adeno-associated virus mediated gene transfer into human leukemia cell lines; efficiencies and integration sites. Blood 88:139a, 1996.
71. 71. Summerfield C, Samulski R. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438-1445, 1998.